FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2153262242> ?p ?o ?g. }

• W2153262242 endingPage "186" @default.
• W2153262242 startingPage "174" @default.
• W2153262242 abstract "Vortioxetine was approved by the U.S. Food and Drug Administration (FDA) in September 2013 for treating major depressive disorder (MDD). Thus far, a number of randomized, double-blind, placebo-controlled clinical trials (RCTs) of vortioxetine have been conducted in patients with MDD. We performed a meta-analysis to increase the statistical power of these studies and enhance our current understanding of the role of vortioxetine in the treatment of MDD.We performed an extensive search of databases and the clinical trial registry. The mean change in total scores on the 24-item Hamilton Rating Scale for Depression (HAM-D) and the Montgomery- Åsberg Depression Rating Scale (MADRS) from the baseline were the primary outcome measures. The secondary efficacy measures were the response and remission rates, as defined by a 50% or greater reduction in HAM-D/MADRS total scores and as a score of 10 or less in the MADRS and 7 or less in the HAM-D total scores at the end of treatment.We included 7 published and 5 unpublished short-term (6-12 wk) RCTs in our meta-analysis. Vortioxetine was significantly more effective than placebo, with an effect size (standardized mean difference [SMD]) of -0.217 (95% confidence interval [CI] -0.313 to -0.122) and with odds ratios (ORs) for response and remission of 1.652 (95% CI 1.321 to 2.067) and 1.399 (95% CI 1.104 to 1.773), respectively. Those treated with vortioxetine did not differ significantly from those treated with selective norepinephrine reuptake inhibitors/agomelatine with regard to the SMD of the primary outcome measure (0.081, -0.062 to 0.223) or for response (OR 0.815, 95% CI 0.585 to 1.135) and remission (OR 0.843, 95% CI 0.575 to 1.238) rates. Discontinuation owing to lack of efficacy (OR 0.541, 95% CI 0.308 to 0.950) was significantly less common among those treated with vortioxetine than among those who received placebo, whereas discontinuation owing to adverse events (AEs; OR 1.530, 95% CI 1.144 to 2.047) was significantly more common among those treated with vortioxetine than among those receiving placebo. There was no significant difference in discontinuation rates between vortioxetine and comparators owing to inefficacy (OR 0.983, 95% CI 0.585 to 1.650), whereas discontinuation owing to AEs was significantly less common in the vortioxetine than in the comparator group (OR 0.728, 95% CI 0.554 to 0.957).Studies examining the role of vortioxetine in the treatment of MDD are limited.Although our results suggest that vortioxetine may be an effective treatment option for MDD, they should be interpreted and translated into clinical practice with caution, as the meta-analysis was based on a limited number of heterogeneous RCTs." @default.
• W2153262242 created "2016-06-24" @default.
• W2153262242 creator A5017929593 @default.
• W2153262242 creator A5018271109 @default.
• W2153262242 creator A5025984426 @default.
• W2153262242 creator A5041007677 @default.
• W2153262242 creator A5062596209 @default.
• W2153262242 creator A5062938278 @default.
• W2153262242 creator A5084299599 @default.
• W2153262242 date "2015-05-01" @default.
• W2153262242 modified "2023-09-24" @default.
• W2153262242 title "Vortioxetine: a meta-analysis of 12 short-term, randomized, placebo-controlled clinical trials for the treatment of major depressive disorder" @default.
• W2153262242 cites W1519680610 @default.
• W2153262242 cites W1831016957 @default.
• W2153262242 cites W1963689439 @default.
• W2153262242 cites W1964931175 @default.
• W2153262242 cites W1968758743 @default.
• W2153262242 cites W1977566467 @default.
• W2153262242 cites W1986215651 @default.
• W2153262242 cites W1987560991 @default.
• W2153262242 cites W1992123212 @default.
• W2153262242 cites W1994256806 @default.
• W2153262242 cites W1997361683 @default.
• W2153262242 cites W2001782289 @default.
• W2153262242 cites W2001856276 @default.
• W2153262242 cites W2002027792 @default.
• W2153262242 cites W2005455004 @default.
• W2153262242 cites W2011606125 @default.
• W2153262242 cites W2016292245 @default.
• W2153262242 cites W2016686222 @default.
• W2153262242 cites W2018151649 @default.
• W2153262242 cites W2020448388 @default.
• W2153262242 cites W2025918112 @default.
• W2153262242 cites W2029732660 @default.
• W2153262242 cites W2048026164 @default.
• W2153262242 cites W2051198709 @default.
• W2153262242 cites W2054766240 @default.
• W2153262242 cites W2059274457 @default.
• W2153262242 cites W2061669920 @default.
• W2153262242 cites W2064453184 @default.
• W2153262242 cites W2066283885 @default.
• W2153262242 cites W2067743319 @default.
• W2153262242 cites W2068597369 @default.
• W2153262242 cites W2071735605 @default.
• W2153262242 cites W2074874853 @default.
• W2153262242 cites W2075394137 @default.
• W2153262242 cites W2077845063 @default.
• W2153262242 cites W2083254291 @default.
• W2153262242 cites W2085758661 @default.
• W2153262242 cites W2094133687 @default.
• W2153262242 cites W2098570599 @default.
• W2153262242 cites W2126777295 @default.
• W2153262242 cites W2128308766 @default.
• W2153262242 cites W2128478870 @default.
• W2153262242 cites W2129953844 @default.
• W2153262242 cites W2131763634 @default.
• W2153262242 cites W2147234629 @default.
• W2153262242 cites W2149154629 @default.
• W2153262242 cites W2150497183 @default.
• W2153262242 cites W2150764016 @default.
• W2153262242 cites W2154874297 @default.
• W2153262242 cites W2157803948 @default.
• W2153262242 cites W2166379049 @default.
• W2153262242 cites W2171340584 @default.
• W2153262242 cites W71228264 @default.
• W2153262242 doi "https://doi.org/10.1503/jpn.140120" @default.
• W2153262242 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4409435" @default.
• W2153262242 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25350320" @default.
• W2153262242 hasPublicationYear "2015" @default.
• W2153262242 type Work @default.
• W2153262242 sameAs 2153262242 @default.
• W2153262242 citedByCount "50" @default.
• W2153262242 countsByYear W21532622422015 @default.
• W2153262242 countsByYear W21532622422016 @default.
• W2153262242 countsByYear W21532622422017 @default.
• W2153262242 countsByYear W21532622422018 @default.
• W2153262242 countsByYear W21532622422019 @default.
• W2153262242 countsByYear W21532622422020 @default.
• W2153262242 countsByYear W21532622422021 @default.
• W2153262242 countsByYear W21532622422022 @default.
• W2153262242 countsByYear W21532622422023 @default.
• W2153262242 crossrefType "journal-article" @default.
• W2153262242 hasAuthorship W2153262242A5017929593 @default.
• W2153262242 hasAuthorship W2153262242A5018271109 @default.
• W2153262242 hasAuthorship W2153262242A5025984426 @default.
• W2153262242 hasAuthorship W2153262242A5041007677 @default.
• W2153262242 hasAuthorship W2153262242A5062596209 @default.
• W2153262242 hasAuthorship W2153262242A5062938278 @default.
• W2153262242 hasAuthorship W2153262242A5084299599 @default.
• W2153262242 hasBestOaLocation W21532622421 @default.
• W2153262242 hasConcept C118552586 @default.
• W2153262242 hasConcept C126322002 @default.
• W2153262242 hasConcept C138496976 @default.
• W2153262242 hasConcept C139719470 @default.
• W2153262242 hasConcept C142724271 @default.
• W2153262242 hasConcept C156957248 @default.
• W2153262242 hasConcept C15744967 @default.
• W2153262242 hasConcept C162324750 @default.

• next